Lummy(SZ:300006) Xin Lang Zheng Quan·2026-01-20 03:36Group 1 - The core viewpoint of the news is that Lai Mei Pharmaceutical's stock has shown fluctuations in price and trading volume, with a recent increase of 2.05% to 4.97 CNY per share, while the company has experienced a year-to-date decline of 3.31% [1] - As of January 9, the number of shareholders for Lai Mei Pharmaceutical increased by 4.40% to 30,700, while the average number of circulating shares per person decreased by 4.21% to 34,403 shares [2] - The company reported a revenue of 581 million CNY for the period from January to September 2025, reflecting a year-on-year decrease of 4.06%, and a net profit attributable to the parent company of -45.92 million CNY, down 73.82% year-on-year [2] Group 2 - Lai Mei Pharmaceutical has a total market capitalization of 5.248 billion CNY, with a trading volume of 84.09 million CNY and a turnover rate of 1.64% [1] - The company's main business segments include specialty drugs (38.24%), large-volume injections (26.27%), and other categories (21.89%), with anti-infection drugs contributing 10.10% and pharmaceutical sales services at 2.31% [1] - Since its A-share listing, Lai Mei Pharmaceutical has distributed a total of 280 million CNY in dividends, with no dividends paid in the last three years [3]